5. Severe Asthma (Acute Severe Asthma / Status Asthmaticus)

Quick Recap

Acute severe asthma (formerly "status asthmaticus"). Nests under Acute Respiratory Failure.

1. Definition

A symptomatic asthma exacerbation that is prolonged or unresponsive to routine bronchodilator therapy, often escalating to respiratory failure requiring ICU admission, intubation, or rescue therapy. ~10% of hospitalized asthma patients require ICU care; ~2% are intubated. Mortality in hospitalized patients 0.5-3%.

2. Pathophysiology

Airway inflammation, bronchoconstriction, and mucus hypersecretion -> severe expiratory airflow limitation -> dynamic hyperinflation (DHI) and intrinsic PEEP (auto-PEEP), analogous to but often more extreme than COPD physiology given younger patients can generate higher intrathoracic pressures. Altered V/Q relationships drive both hypoxemia and (in extremis) hypercapnia. Onset can be rapid (hours — allergen, irritant, exercise, psychosocial stress, illicit inhalants, aspirin/NSAID/beta-blocker sensitivity) or gradual (days — typically viral/atypical infection).

Recognized near-fatal asthma clusters: (1) older, female, severe persistent disease with frequent hospitalizations despite adherence; (2) smokers with intermediate severity, psychiatric comorbidity, frequent ventilation need; (3) younger, male, allergic, poor engagement with care/medication adherence.

3. Immediate Stabilization (ABCDE)

Airway: Absolute intubation indications: cardiac/respiratory arrest, severe bradypnea, extreme exhaustion, altered sensorium. Use largest feasible ETT (8.0 mm in adults) to reduce airway resistance and allow suctioning/bronchoscopy. Ketamine, propofol, or etomidate for RSI induction — avoid excessive bag-mask ventilation pre-intubation (worsens DHI).

Breathing:

• NIV (CPAP or BiPAP) reasonable as initial therapy IF patient is alert, cooperative, able to protect airway and tolerate a mask — reduces work of breathing; evidence base smaller than for COPD
• Ventilator strategy — goal is to unload respiratory muscles and minimize DHI, NOT normalize gas exchange:
• Mode: volume-controlled
• Minute ventilation ~10 L, Vt 6-8 mL/kg, RR 10-14
• Inspiratory flow 60-80 L/min, I:E 1:3 to 1:5 (prolonged expiratory time is the key lever against DHI)
• PEEP 5 cmH2O (external PEEP kept low; do not chase auto-PEEP with high extrinsic PEEP)
• FiO2 titrated for SpO2 >90%
• Goal: intrinsic PEEP <20 cmH2O, plateau pressure <30 cmH2O — accept permissive hypercapnia to achieve this
• Increasing flow rate/square waveform has minimal added benefit once minute ventilation is limited

Circulation: Post-intubation hypotension is common — due to positive pressure interacting with pre-existing DHI/auto-PEEP, hypovolemia, and sedation. Manage with sedation, liberal IV fluids, and ventilator strategies to reduce DHI; if severe, briefly disconnect the circuit to allow full exhalation and relieve intrathoracic pressure.

Disability: altered sensorium is an absolute intubation indication; monitor pulsus paradoxus as a bedside severity marker.

Exposure: watch for pneumothorax (barotrauma risk from vigorous bagging or high DHI).

Checklist:

4. Focused History

Trigger identification (allergen, irritant, exercise, infection, NSAID/aspirin/beta-blocker exposure, illicit inhalant use, psychosocial stress); prior ICU admission or intubation for asthma (major risk factor); hospitalization/ED visit frequency in past year; SABA canister use (>2/month = high risk); current or recently withdrawn oral corticosteroid use; comorbid cardiovascular disease; smoking; socioeconomic/access barriers to care.

5. Examination + POCUS

Wheeze (its ABSENCE in a severely obstructed patient is an ominous "silent chest" sign, not reassurance), prolonged expiratory phase, accessory muscle use, pulsus paradoxus, inability to speak in full sentences, diaphoresis, tachycardia.

POCUS: exclude pneumothorax, especially post-intubation or with sudden hemodynamic deterioration on the ventilator.

6. Syndrome Identification

Severe lower airway obstruction/bronchospasm syndrome with dynamic hyperinflation — the ventilator management priority (minimizing DHI) differs from most other respiratory failure syndromes and should be recognized early.

7. Differential Diagnosis

8. Severity Assessment

GINA (Global Initiative for Asthma) severity classification using PEF (peak expiratory flow): moderate (PEF 60-80% predicted), severe (PEF <60%, risk factors for near-fatal asthma present). Risk factors for death from asthma: lower socioeconomic status, female sex, Black race/ethnicity, smoking, "labile" asthma with high PEF variability, blood eosinophilia, poor dyspnea perception, prior intubation/ICU admission for asthma, >=2 hospitalizations or >=3 ED visits in past year, hospitalization/ED visit in past month, high SABA use, current/recently withdrawn oral steroids, comorbid cardiovascular disease.

9. Investigations

• Bedside: PEF (if able to perform), ABG if severe/deteriorating, SpO2, POCUS (exclude pneumothorax)
• Labs: CBC (eosinophilia), electrolytes (beta-agonist therapy causes hypokalemia/hyperglycemia/lactic acidosis)
• Imaging: CXR to exclude pneumothorax, pneumonia, or alternate diagnosis — not routinely diagnostic of asthma itself
• Note: a "normal" or rising PaCO2 in a tachypneic asthmatic is a red flag for impending respiratory failure, not reassurance

10. POCUS

Primarily used to exclude pneumothorax (a real risk given DHI, barotrauma from bagging, and high intrathoracic pressures) rather than to characterize the primary process.

11. Evidence-Based Management

Inhaled bronchodilators (first-line, continuous/frequent):

• Albuterol (SABA) nebulized, continuous or every 20 min initially
• Ipratropium (SAMA) 0.5 mg nebulized every 20 min with albuterol for first 36h — improves airflow limitation
• In intubated patients: deliver via MDI with spacer/adapter in the inspiratory limb
• Long-acting beta-agonists NOT for acute treatment (may continue as add-on in stable/outpatient phase)
• IV beta-agonists not recommended — no efficacy advantage over aerosol, more toxicity

Corticosteroids (critical for resolution):

• IV preferred for critically ill patients; no benefit to massive initial dose
• Methylprednisolone 100-125 mg IV once, then 40-60 mg IV every 6-12h (~2 mg/kg/day or less)
• Taper after 36-48h based on response
• COVID-19-associated: dexamethasone 6 mg IV daily may suffice

Magnesium sulfate: IV MgSO4 2g over 20 min — relatively safe, evidence for added efficacy over standard therapy is weak; no data supporting repeat/ongoing dosing. Inhaled magnesium with bronchodilators may offer modest additional benefit (weaker evidence).

Antibiotics: NOT routine (most exacerbations are viral). Reserve for fever, purulent sputum, or evidence of pneumonia/bacterial sinusitis.

Ketamine: consider for sedation in mechanically ventilated patients or as adjunct in refractory cases not responding to IV beta-agonist/steroids — bronchodilatory properties, but evidence is limited; ensure intubation readiness before use.

Not recommended / limited use:

• Methylxanthines (theophylline/aminophylline): not recommended for initial treatment, similar efficacy to beta-agonists with more toxicity
• Epinephrine: no proven advantage over inhaled bronchodilators; reserve for suspected anaphylaxis or patients unable to cooperate with inhaled therapy (0.5 mg of 1:1000 SC every 20 min, up to 3 doses)
• Heliox: theoretical benefit (reduced turbulent flow) via improved aerosol delivery; limited by need for lower FiO2; use only where institutional experience exists

Refractory/rescue therapies (mechanically ventilated, dyssynchrony despite sedation):

• Neuromuscular blockade as intermittent boluses with train-of-four monitoring (avoid continuous infusion — myopathy risk compounded by concurrent steroids)
• Inhaled anesthetics (sevoflurane, isoflurane, halothane) for refractory bronchospasm
• ECMO as salvage for refractory hypoxemic/hypercapnic failure — limited but promising retrospective data; no RCT evidence yet

12. Organ Support

Ventilation per DHI-minimizing strategy above; liberal IV fluids for post-intubation hypotension; correction of beta-agonist-induced hypokalemia; nutrition and standard ICU supportive care once stabilized.

13. Disease-Specific Therapy

See Section 11 in full. No disease-modifying acute therapy beyond bronchodilators/steroids/magnesium; biologics (omalizumab, mepolizumab, etc.) are outpatient maintenance therapies, not acute rescue agents.

14. Consultation Matrix

15. Monitoring Framework

Continuous SpO2/work-of-breathing assessment; serial ABG if severe/ventilated; plateau pressure and auto-PEEP monitoring in ventilated patients (goal <30 and <20 cmH2O respectively); electrolytes (K+, glucose) given beta-agonist/steroid effects; watch for pneumothorax.

16. ICU Bundle Checklist (Daily)

17. Complications

Pneumothorax/barotrauma (DHI-related), post-intubation hypotension, arrhythmia (beta-agonist/theophylline toxicity if used), ICU-acquired weakness (steroid + NMB combination — avoid continuous NMB infusion), hypokalemia, hyperglycemia. Prevention: DHI-minimizing ventilation, intermittent (not continuous) NMB dosing, electrolyte monitoring. Rescue: chest tube for pneumothorax, exhalation/disconnect maneuver for severe auto-PEEP-related hypotension, ECMO for refractory failure.

18. Escalation & De-escalation

Escalate: poor response within 1-2h of maximal therapy, worsening PEF <30%, PaCO2 >45 with PaO2 <60, drowsiness/confusion, silent chest -> ICU admission, consider intubation.

Wean: improving PEF (>60-70% predicted), sustained response 60 min after last treatment, normal physical exam, SpO2 >95% -> transition to standard inhaled therapy, consider discharge planning.

19. ICU Discharge Criteria

PEF >60-70% predicted/personal best sustained on oral/inhaled medication, no accessory muscle use, extubated (if previously ventilated) and stable, electrolytes corrected, steroid taper initiated, discharge action plan and inhaler technique reviewed.

20. Documentation & Medicolegal Checklist

21. Key Guidelines

Global Initiative for Asthma (GINA) Strategy Report; institutional/ATS guidance on acute severe asthma management as summarized in Washington Manual of Critical Care Ch. 12.

22. Landmark Trials / Key Evidence

• Camargo CA et al. Continuous vs intermittent beta-agonists in acute asthma (Cochrane meta-analysis) — informs continuous nebulization practice.
• Knightly R et al. Inhaled magnesium sulfate in acute asthma (Cochrane review, 2017) — modest benefit as adjunct to bronchodilators.
• La Via L et al. Ketamine in refractory severe asthma exacerbations — systematic review of prospective studies, evidence still limited.
• Retrospective ECMO-in-asthma analyses suggesting mortality benefit as salvage therapy — no RCT yet.

23. Controversies

Optimal role and dosing of IV vs inhaled magnesium remains unsettled. Ketamine's role as a primary bronchodilator adjunct (vs sedation-only) is not well established. ECMO candidacy criteria in refractory asthma are not standardized and evidence remains retrospective/observational. Heliox utility is limited by institutional experience and hypoxemia constraints, and is not broadly recommended.

24. References

1. Sattler L, Sumino K. Acute Severe Asthma. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 12).
2. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, current edition.
3. Camargo CA Jr, Spooner CH, Rowe BH. Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database Syst Rev. 2003(4):CD001115.
4. Knightly R, Milan SJ, Hughes R, et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database Syst Rev. 2017;11:CD003898.
5. La Via L, Sanfilippo F, Cuttone G, et al. Use of ketamine in patients with refractory severe asthma exacerbations: systematic review. Eur J Clin Pharmacol. 2022;78(10):1613-1622.
6. Garner O, Ramey JS, Hanania NA. Management of life-threatening asthma: severe asthma series. Chest. 2022;162(4):747-756.
7. Chugh K. Acute Severe Asthma. ICU Protocols: A Step-wise Approach, 2nd ed. Springer; 2020.